Target intelligence / Profile preview

Presynaptic glutamatergic terminal

Molecular classification
Cellular structure, Synaptic compartment
01

Overview

Presynaptic glutamatergic terminals are the specialized distal endings of axons that release glutamate, the primary excitatory neurotransmitter in the vertebrate central nervous system [1]. These terminals contain the machinery necessary for glutamate synthesis, packaging into synaptic vesicles via vesicular glutamate transporters (VGLUTs), and calcium-dependent exocytosis into the synaptic cleft [2]. They are critical for excitatory signaling and synaptic plasticity, which underlie learning and memory [3]. Dysregulation of these terminals, leading to either excessive glutamate release (excitotoxicity) or insufficient transmission, is implicated in various neurological and psychiatric disorders, including epilepsy, stroke, and schizophrenia [4]. Pharmacological intervention often focuses on modulating release through presynaptic receptors (e.g., mGluRs) or ion channels (e.g., N-type calcium channels) to restore normal glutamatergic tone [5, 6].

Other names
Glutamatergic nerve terminalPresynaptic boutonGlutamatergic synapse (presynaptic side)Glutamatergic axonal terminal
02

Mechanism of action

Modulation of glutamate release via inhibition of voltage-gated calcium channels (e.g., N-type or P/Q-type), binding to synaptic vesicle proteins (SV2A), or activation of inhibitory presynaptic metabotropic glutamate receptors (autoreceptors).

03

Biological functions

Neurotransmitter releaseSynaptic transmissionGlutamate homeostasisSynaptic plasticityCalcium-dependent exocytosis
04

Disease associations

EpilepsyNeurodegenerative diseaseSchizophreniaChronic painStrokeAmyotrophic lateral sclerosis
05

Safety considerations

Excitotoxicity due to excessive glutamateCognitive impairment due to suppressed excitatory transmissionSedationAtaxiaPotential for withdrawal symptoms or rebound hyperexcitability
06

Interacting drugs

Gabapentin

5 more in the full profile.

07

Biomarkers

Vesicular glutamate transporter 1 (VGLUT1)Vesicular glutamate transporter 2 (VGLUT2)Glutamate levels via Magnetic Resonance Spectroscopy (MRS)Synaptic vesicle protein 2A (SV2A) PET imaging

Beyond the preview

Go deeper on Presynaptic glutamatergic terminal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presynaptic glutamatergic terminal.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call